{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:14Z","timestamp":1787028614314,"version":"build-2736575974"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL\/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 \u00b1 0.8 years. The following changes were observed: HbA1c \u22121.0% \u00b1 1.9 (p &lt; 0.001), eGFR \u22127.0 mL\/min \u00b1 13.3 (p &lt; 0.001), albuminuria \u221223.9 mg\/g creatinine \u00b1 144.5 (p = 0.118), bodyweight \u22123.0 kg \u00b1 5.8 (p &lt; 0.001), systolic blood pressure \u22126 mmHg \u00b1 22 (p = 0.01), diastolic blood pressure \u22122 mmHg \u00b1 14 (p = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL\/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy.<\/jats:p>","DOI":"10.3390\/jcm10040571","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T20:31:51Z","timestamp":1612384311000},"page":"571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-4064","authenticated-orcid":false,"given":"Maximilian","family":"Hopf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Kloos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0465","authenticated-orcid":false,"given":"Ulrich Alfons","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Practice for Endocrinology and Diabetology, Centre for Ambulatory Medicine, Jena University Hospital, 07743 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-7322","authenticated-orcid":false,"given":"Nicolle","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99:1","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPAREG-OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG Outcome investigators. empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Declare\u2013TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_10","first-page":"629","article-title":"Assessing social inequality in microcensus data and German national health examination survey","volume":"65","author":"Dulon","year":"2003","journal-title":"Gesundheitswesen"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/dme.14262","article-title":"Renal outcomes with the newer antidiabetic drugs: The era before and after credence","volume":"37","author":"Rajani","year":"2020","journal-title":"Diabet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.33549\/physiolres.933120","article-title":"Clinically meaningful blood pressure reductions with low intensity isometric handgrip exercise. a randomized trial","volume":"65","author":"Hess","year":"2016","journal-title":"Physiol. Res."},{"key":"ref_14","first-page":"e7201:1","article-title":"Long-term efficacy and safety of sodium-glucose Cotransporter-2 inhibitors as Add-On to Metformin treatment in the management of Type 2 diabetes mellitus: A meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"Norton","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The claude bernard lecture 2009","volume":"53","year":"2010","journal-title":"Diabetologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/j.0022-0337.2002.66.10.tb03584.x","article-title":"Intentional use of the Hawthorne effect to improve oral hygiene compliance in orthodontic patients","volume":"66","author":"Feil","year":"2002","journal-title":"J. Dent. Educ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e001238:1","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"McGovern","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_19","first-page":"1783","article-title":"Obesity and risk of infections: Results from men and women in the Swedish National March Cohort","volume":"48","author":"Ghilotti","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.idc.2013.10.004","article-title":"Diagnosis and management of urinary tract infection in older adults","volume":"28","author":"Rowe","year":"2014","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107587:1","DOI":"10.1016\/j.jdiacomp.2020.107587","article-title":"Effects of sodium glucose Co-Transporter 2 inhibitors on genital infections in female patients with Type 2 diabetes mellitus\u2014Real world data analysis","volume":"34","author":"Nakhleh","year":"2020","journal-title":"J. Diabetes Complicat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:19:34Z","timestamp":1760159974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jcm10040571"],"URL":"https:\/\/doi.org\/10.3390\/jcm10040571","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}